Answers are grounded in this paper and cite their sources.
Background SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a candidate contributor to airway inflammation and remodeling. We explored associations between the SERPINE1 −675 4G/5G polymorphism and outcomes during tezepelumab treatment. Methods This prospective multicenter cohort enrolled 45 Japanese adults; 44 completed 52 weeks (4G/4G, 21; 4G/5G, 15; 5G/5G, 8). Genotyping of pretreatment samples occurred after follow-up, with physicians and outcome assessors blinded to genotype. The approved protocol specified negative binomial regression comparing 4G carriers with 5G/5G, adjusted for prior-year exacerbations. Additional adjustment for prior biologic exposure, ICS category, and maintenance OCS use was retained as exploratory. Results Forty-seven exacerbations occurred over 44 patient-years, defining one analysis year as 52 weeks. Crude annualized exacerbation rates were 1.14, 0.73, and 1.50 events/patient-year across the three genotypes; 30 participants had no exacerbations. The protocol-specified adjusted incidence rate ratio was 5.06 (95% confidence interval, 0.51–49.97), compared with 0.65 (0.11–3.69) unadjusted and 3.28 (0.34–31.29) with expanded adjustment. These estimates were too imprecise and model-dependent for reliable interpretation. An exploratory three-genotype FeNO comparison at week 52 yielded P = 0.00353; post hoc false discovery rate adjustment gave q = 0.04594 across 13 secondary tests and q = 0.08127 across 23 secondary/exploratory tests. The 0.05 threshold was met only in the smaller family; both adjustments remain exploratory. Conclusions The data do not establish either a clinically useful genotype association or its absence. Sparse outcomes, baseline imbalance, and heterogeneous treatment histories limit inference. Without a comparator treatment, this study cannot determine whether genotype modifies the treatment effect of tezepelumab. Trial registration: UMIN000052531, October 18, 2023.
No takes yet. Share an insight, caveat, or question.
Fukahori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: